Events

The next generation of Adamed Pharma joins a summit with the King and Prime Minister of Spain

30 April 2026

Karolina Adamkiewicz, MD, PhD, represented Adamed Pharma at the Invest in Spain Summit 2026 in Madrid. The Business Development Director of the Polish pharmaceutical and biotechnology company participated in meetings with King Felipe VI, Prime Minister Pedro Sánchez and government representatives, including the Minister of Health. Her participation demonstrates that succession at Adamed Pharma is already at an advanced stage. 

Seventeen years in Spain and now its own factory 

Adamed has operated in Spain since 2009, developing its commercial activities. Spain is now the company’s largest market outside Poland. Adamed is entering the next stage of its growth by adding manufacturing operations to its presence in the country through the acquisition of Sanofi’s plant in Riells near Barcelona. 

“Spain is a market of strategic importance to Adamed. We have been present here for 17 years, and our medicines support patients in key areas including oncology, cardiology and neuropsychiatry. Today we want to be even closer to the market and to patients, which is why we are acquiring the Riells plant and becoming a local manufacturer. This is an important step in building Adamed’s strong position in Europe and a platform for further expansion, including in Latin America,” said Karolina Adamkiewicz, MD, PhD, Business Development Director at Adamed Pharma. 

The Riells factory will provide Adamed with a manufacturing centre that will enable the company to double production, diversify manufacturing locations, improve supply-chain resilience and strengthen medicine security in Europe. For patients, this means greater continuity of treatment and a lower risk of medicine shortages. 

The Riells plant employs more than 200 people. Adamed intends to preserve employment and current working conditions. The factory manufactures approximately 75 million packs of medicines annually. Adamed will invest in modernising production, infrastructure and logistics and adapting the facility to current and new products. 

A summit attended by the King and Prime Minister, and discussions with three ministries 

During the Invest in Spain Summit 2026, Adamed’s investment in Spain was one of the main topics discussed by Karolina Adamkiewicz and Bernardo de Rafael Töpfer, General Manager of Adamed Laboratorios, with the Minister of Health and representatives of the Ministry of Industry and Tourism and the Ministry of Economy, Trade and Enterprise. 

The talks covered plans for the development of the Riells plant, pharmaceutical regulations, support for foreign investors and Spain’s role in Adamed’s further international expansion. 

“The Invest in Spain Summit offers an opportunity for direct dialogue with top-level decision-makers. Such meetings are crucial for companies planning long-term investments,” said Bernardo de Rafael Töpfer, General Manager of Adamed Laboratorios. 

The Invest in Spain Summit is organised by ICEX, the Spanish government agency. The event brought together more than 150 representatives of 75 companies from 25 countries. The presence of Spain’s highest authorities underlined the strategic importance of foreign investment to the country. 

Succession at Adamed Pharma is at an advanced stage 

Karolina Adamkiewicz represents the third generation of the family involved in the company’s development. She has served as Business Development Director at Adamed Pharma for one year, using her medical experience and expertise to support the company’s growth and international expansion. 

She is a graduate of the University of Cambridge and King’s College London, and received her PhD in medical sciences from the Medical University of Warsaw. She holds a specialist qualification in internal medicine, MRCP (UK), and an MBA from INSEAD. 

Adamed is a family-owned company with 100% Polish capital and is present in dozens of markets across six continents.